乳がん治療薬の市場規模・予測（2020年～2030年）、世界・地域シェア、動向、成長機会分析レポート対象範囲薬物療法別［標的薬物療法（アベマシクリブ、アド-トラスツズマブ・エムタンシン、パルボシクリブ、トラスツズマブ、その他の標的薬物療法）、ホルモン薬物療法（選択的エストロゲン受容体モジュレーター、アロマターゼ阻害剤、選択的エストロゲン受容体ダウンレギュレーター）、化学療法、免疫療法／生物学的療法]、乳癌タイプ（ホルモン受容体乳癌、HER2+乳癌、トリプルネガティブ乳癌）、流通チャネル（病院薬局、ドラッグストア・小売薬局、オンライン薬局）、地域（北米、欧州、アジア太平洋、中東・アフリカ、中南米）

Breast Cancer Therapeutics Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

乳がん治療薬の市場規模・予測（2020-2030年）、世界・地域シェア、動向、成長機会分析対象範囲薬物療法［標的薬物療法（アベマシクリブ、アド-トラスツズマブ・エムタンシン、パルボシクリブ、トラスツズマ... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
The Insight Partners ザ・インサイトパートナーズ	2023年10月4日	US$4,550 シングルユーザライセンスライセンス・価格情報注文方法はこちら	204	英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

サマリー

乳がん治療薬の市場規模・予測（2020-2030年）、世界・地域シェア、動向、成長機会分析

対象範囲薬物療法［標的薬物療法（アベマシクリブ、アド-トラスツズマブ・エムタンシン、パルボシクリブ、トラスツズマブ、その他の標的薬物療法）、ホルモン薬物療法（選択的エストロゲン受容体モジュレーター、アロマターゼ阻害剤、選択的エストロゲン受容体ダウンレギュレーター）、化学療法、免疫療法/生物学的療法］、乳がんの種類（ホルモン受容体、HER2+、トリプルネガティブ乳がん）、流通チャネル（病院薬局、ドラッグストア・小売薬局、オンライン薬局）、地域（北米、欧州、アジア太平洋、中東・アフリカ、中南米）

乳がん治療薬の市場規模は、2022年の310億7,352万米ドルから2030年には639億6,705万米ドルに成長すると予測され、2022年から2030年までの年平均成長率は9.4%を記録すると推定される。

乳がんは、乳房の細胞が制御不能に増殖する病気である。乳がんにはいくつかの形態がある。どの乳房細胞が癌化するかによって乳癌の種類が決まります。乳管または小葉は、ほとんどの乳癌が始まる場所です。血液とリンパ管は、乳癌が乳房の外に移動する2つの方法です。乳癌の治療は癌の病期によって異なります。化学療法、放射線療法、ホルモン療法、手術などがある。乳がん治療薬市場の成長は、乳がんの負担が増加していることと、いくつかの診断・スクリーニングプログラムが開始されたことに起因している。

個別化医療では、遺伝的体質などに基づいて個々の患者に合わせた治療計画が立てられる。このアプローチでは、各患者のがんの特徴を考慮するため、高度に的を絞った効果的な治療が可能になる。ゲノミクスと分子診断学の進歩により、個別化医療は乳がん治療において実行可能な選択肢となった。医療従事者は、患者の腫瘍を分子レベルで分析することにより、がんの成長を促す特定の遺伝子変異やバイオマーカーを特定することができる。この情報をもとに、標的療法や免疫療法など、特定の患者にとって最も効果的と思われる治療法を選択することができる。乳がん治療における個別化医療の利用は、患者の転帰を大幅に改善する可能性を秘めている。例えば、2022年2月、NIHの研究者らは、転移性乳癌患者の治療に患者の腫瘍と闘う免疫細胞を使用する免疫療法の実験的形態である個別化乳癌治療アプローチを開発し、個別化医療を前進させた。

個々の患者に合わせた治療法を提供することで、医療従事者は治療が成功する可能性を高め、不必要な副作用のリスクを減らすことができる。患者の転帰を改善するだけでなく、個別化医療には経済的なメリットもある。より効果が期待できる治療法を選択することで、医療提供者は効果のない治療に伴う医療費を削減し、不必要な出費を避けることができる。ゲノミクスと分子診断学の進歩に伴い、個別化医療は今後ますます利用しやすくなり、標準的な治療プロトコルに組み込まれるようになるだろう。そのため、個別化医療の利用拡大が乳がん治療薬市場に新たな成長トレンドをもたらすと予想される。

流通チャネルに基づく洞察

流通チャネルに基づき、乳がん治療薬市場は病院薬局、ドラッグストアおよび小売薬局、オンライン薬局に区分される。2022年には、病院薬局セグメントが最大の市場シェアを占めている。病院薬局は、乳がん治療薬の管理において重要な役割を果たしている。調剤や調剤、医薬品の安全性の監視、投薬管理、患者への教育などを担っている。乳がんは世界的に最も蔓延しているがんの1つであり、効果的な治療薬に対する需要は着実に高まっている。病院薬局は、乳がんに関連する化学療法薬やその他の治療薬を調達、保管、調剤し、患者が適切な治療を時間内に受けられるようにする役割を担っています。また、これらの薬剤の在庫や保管を管理する権限もあり、厳格な規則に従って保管され、取り扱われていることを保証している。がん専門医や医療チームとの協力的な取り組みにより、乳がん患者は治療期間を通じて最適で個別化された治療薬と包括的なケアを受けることができます。病院薬局は、タイムリーで効果的な乳がん治療を提供する上で重要な役割を果たしており、闘病中の患者の転帰に大きな影響を与えている。

しかし、オンライン薬局セグメントは、2022年から2030年の間に最も高いCAGRを記録すると予想されている。オンライン薬局は、化学療法薬から支持療法まで幅広い乳がん治療薬を提供し、多くの場合、宅配サービスも行っている。オンライン薬局は、処方箋の確認と規制遵守の維持を保証し、医療システムの整合性を維持する上で重要な役割を果たしている。また、バラバラの買い物を好む患者や、治療のために移動が制限されている患者にも利便性を提供している。また、患者が価格を比較し、より幅広い乳がん治療薬の選択肢にアクセスすることも可能である。宅配や患者サポートなどのサービスにより、オンライン薬局は進化を続け、乳がん治療の体験を変え、世界中の患者の地理的障壁を取り払う。また、使い勝手の良さから、治療薬を入手するためにこれらの薬局を利用する患者も増えており、このセグメントの成長を後押ししている。

欧州は同市場において2番目に主要な地域である。乳がんは英国でよく見られるがんの一種である。国民保健サービス（NHS）のデータでは、英国では女性の約7人に1人が一生の間に乳がんと診断されている。毎年、〜55,000人の女性が乳がんと診断されている。

乳がん患者を新規治療薬で治療したいという医療業界からの需要が高まっているため、研究開発への投資が活発化し、市場の成長に拍車をかけている。企業は競争力を維持し、最先端の革新的な製品を顧客に提供するために研究開発に投資している。2021年10月には、新しい抗体治療薬であるトロデルヴィが、国内で「トリプルネガティブ乳がん」と呼ばれる攻撃性の高いがんの治療薬として認可された。2021年11月、サノフィは1億8,000万米ドルを投資し、4種類の癌の発見と開発プログラムに従事するフランス系米国人のAI新興企業であるOwkin社と、支払総額9,000万米ドルの新たな戦略的提携を締結した。この提携は、乳がん、肺がん、多発性骨髄腫などの中核領域におけるサノフィの開発中のオンコロジー・ポートフォリオを支援し、臨床試験デザインを強化し、疾患や治療結果の予測バイオマーカーを検出するものである。

イタリア政府と国立医療機関は、乳がんの早期発見と治療のためにいくつかのイニシアチブを立ち上げている。これらのプログラムには、50～69歳の女性を対象とした無料のマンモグラフィや、全国的な乳がん検診プログラムが含まれる。さらに、EURACTIVが提供した情報によると、イタリアでは専門的な乳腺治療室の数が2012年の84から2020年には173へと大幅に増加している。乳腺科の数が増えることは、医療専門家が乳がん患者に治療を提供するのに役立つ。このように、上記の要因がこの地域の市場成長を支えている。

American Cancer S0 Society（米国癌学会）、World Health Organization（世界保健機関：WHO）、National Institutes of Health（米国国立衛生研究所：NIH）、US FDA（米国食品医薬品局：FDA）などは、乳癌治療薬市場レポート作成時に参照した一次および二次情報源の1つです。

ページTOPに戻る

TABLE OF CONTENTS

1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Breast Cancer Therapeutics Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. Breast Cancer Therapeutics Market - Key Industry Dynamics
5.1 Key Market Drivers
5.1.1 Growing Burden of Breast Cancer
5.1.2 Launch of Several Diagnostics and Screening Programs
5.2 Key Market Restraints
5.2.1 High Cost of Diagnosis and Treatment
5.3 Key Market Opportunities
5.3.1 Increased Support from Government and Private Organizations
5.4 Key Future Trends
5.4.1 Increasing Use of Personalized Medicine
5.5 Impact Analysis:
6. Breast Cancer Therapeutics Market - Global Market Analysis
6.1 Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 2030
7. Global Breast Cancer Therapeutics Market Revenue and Forecast to 2030 by Drug Therapy
7.1 Overview
7.2 Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
7.3 Targeted Drug Therapy
7.3.1 Overview
7.3.2 Targeted Drug Therapy: Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
7.3.2.1 Global Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020 2030 (US$ Million)
7.4 Hormonal Drug Therapy
7.4.1 Overview
7.4.2 Hormonal Drug Therapy: Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
7.5 Chemotherapy
7.5.1 Overview
7.5.2 Chemotherapy: Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
7.6 Immunotherapy/ Biological Therapy
7.6.1 Overview
7.6.2 Immunotherapy/ Biological Therapy: Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
8. Global Breast Cancer Therapeutics Market Revenue and Forecast to 2030 by Breast Cancer Type
8.1 Overview
8.2 Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
8.3 Hormone Receptor
8.3.1 Overview
8.3.2 Hormone Receptor: Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
8.4 HER2+ (human epidermal growth factor receptor 2)
8.4.1 Overview
8.4.2 HER2+: Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
8.5 Triple-Negative Breast Cancer
8.5.1 Overview
8.5.2 Triple-Negative Breast Cancer: Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
9. Global Breast Cancer Therapeutics Market Revenue and Forecast to 2030 by Distribution Channel
9.1 Overview
9.2 Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
9.3 Hospital Pharmacies
9.3.1 Overview
9.3.2 Hospital Pharmacies: Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
9.4 Drug Store and Retail Pharmacies
9.4.1 Overview
9.4.2 Drug Store and Retail Pharmacies: Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
9.5 Online Pharmacies
9.5.1 Overview
9.5.2 Online Pharmacies: Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
10. Breast Cancer Therapeutics Market - Geographical Analysis
10.1 North America Breast Cancer Therapeutics Market, Revenue and Forecast To 2030
10.1.1 Overview
10.1.2 North America Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.1.3 North America: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.1.3.1 North America: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.1.3.2 North America: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.1.4 North America: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.1.5 North America: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.1.6 North America Breast Cancer Therapeutics Market, by Country
10.1.6.1 US
10.1.6.1.1 US Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.1.2 US: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.1.6.1.2.1 US: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.1.6.1.2.2 US: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.1.6.1.3 US: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.1.6.1.4 US: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.1.6.2 Canada
10.1.6.2.1 Canada Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.2.2 Canada: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.1.6.2.2.1 Canada: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.1.6.2.2.2 Canada: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.1.6.2.3 Canada: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.1.6.2.4 Canada: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.1.6.3 Mexico
10.1.6.3.1 Mexico Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.3.2 Mexico: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.1.6.3.2.1 Mexico: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.1.6.3.2.2 Mexico: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.1.6.3.3 Mexico: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.1.6.3.4 Mexico: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.2 Europe Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
10.2.1 Overview
10.2.2 Europe Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.3 Europe: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.2.3.1 Europe: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.2.3.2 Europe: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.2.4 Europe: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.2.5 Europe: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.2.6 Europe Breast Cancer Therapeutics Market, by Country
10.2.6.1 UK
10.2.6.1.1 UK Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.1.2 UK: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.2.6.1.2.1 UK: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.2.6.1.2.2 UK: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.2.6.1.3 UK: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.2.6.1.4 UK: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.2.6.2 Germany
10.2.6.2.1 Germany Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.2.2 Germany: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.2.6.2.2.1 Germany: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.2.6.2.2.2 Germany: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.2.6.2.3 Germany: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.2.6.2.4 Germany: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.2.6.3 France
10.2.6.3.1 France Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.3.2 France: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.2.6.3.2.1 France: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.2.6.3.2.2 France: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.2.6.3.3 France: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.2.6.3.4 France: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.2.6.4 Italy
10.2.6.4.1 Italy Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.4.2 Italy: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.2.6.4.2.1 Italy: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.2.6.4.2.2 Italy: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.2.6.4.3 Italy: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.2.6.4.4 Italy: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.2.6.5 Spain
10.2.6.5.1 Spain Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.5.2 Spain: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.2.6.5.2.1 Spain: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.2.6.5.2.2 Spain: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.2.6.5.3 Spain: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.2.6.5.4 Spain: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.2.6.6 Rest of Europe
10.2.6.6.1 Rest of Europe Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.6.2 Rest of Europe: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.2.6.6.2.1 Rest of Europe: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.2.6.6.2.2 Rest of Europe: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.2.6.6.3 Rest of Europe: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.2.6.6.4 Rest of Europe: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.3 Asia Pacific Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
10.3.1 Overview
10.3.2 Asia Pacific Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.3 Asia Pacific: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.3.3.1 Asia Pacific: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.3.3.2 Asia Pacific: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.3.4 Asia Pacific: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.3.5 Asia Pacific: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.3.6 Asia Pacific Breast Cancer Therapeutics Market, by Country
10.3.6.1 China
10.3.6.1.1 China Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.1.2 China: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.3.6.1.2.1 China: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.3.6.1.2.2 China: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.3.6.1.3 China: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.3.6.1.4 China: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.3.6.2 Japan
10.3.6.2.1 Japan Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.2.2 Japan: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.3.6.2.2.1 Japan: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.3.6.2.2.2 Japan: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.3.6.2.3 Japan: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.3.6.2.4 Japan: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.3.6.3 India
10.3.6.3.1 India Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.3.2 India: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.3.6.3.2.1 India: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.3.6.3.2.2 India: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.3.6.3.3 India: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.3.6.3.4 India: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.3.6.4 Australia
10.3.6.4.1 Australia Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.4.2 Australia: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.3.6.4.2.1 Australia: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.3.6.4.2.2 Australia: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.3.6.4.3 Australia: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.3.6.4.4 Australia: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.3.6.5 South Korea
10.3.6.5.1 South Korea Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.5.2 South Korea: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.3.6.5.2.1 South Korea: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.3.6.5.2.2 South Korea: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.3.6.5.3 South Korea: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.3.6.5.4 South Korea: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.3.6.6 Rest of Asia Pacific
10.3.6.6.1 Rest of Asia Pacific Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.2 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.3.6.6.2.1 Rest of Asia Pacific: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.3.6.6.2.2 Rest of Asia Pacific: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.3.6.6.3 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.3.6.6.4 Rest of Asia Pacific: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.4 Middle East & Africa Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
10.4.1 Overview
10.4.2 Middle East & Africa Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.4.3 Middle East & Africa: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.4.3.1 Middle East & Africa: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.4.3.2 Middle East & Africa: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.4.4 Middle East & Africa: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.4.5 Middle East & Africa: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.4.6 Middle East & Africa Breast Cancer Therapeutics Market, by Country
10.4.6.1 Saudi Arabia
10.4.6.1.1 Saudi Arabia Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.4.6.1.2 Saudi Arabia: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.4.6.1.2.1 Saudi Arabia: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.4.6.1.2.2 Saudi Arabia: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.4.6.1.3 Saudi Arabia: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.4.6.1.4 Saudi Arabia: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.4.6.2 UAE
10.4.6.2.1 UAE Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.4.6.2.2 UAE: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.4.6.2.2.1 UAE: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.4.6.2.2.2 UAE: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.4.6.2.3 UAE: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.4.6.2.4 UAE: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.4.6.3 South Africa
10.4.6.3.1 South Africa Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.4.6.3.2 South Africa: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.4.6.3.2.1 South Africa: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.4.6.3.2.2 South Africa: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.4.6.3.3 South Africa: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.4.6.3.4 South Africa: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.4.6.4 Rest of Middle East & Africa
10.4.6.4.1 Rest of Middle East & Africa Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.4.6.4.2 Rest of Middle East & Africa: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.4.6.4.2.1 Rest of Middle East & Africa: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.4.6.4.2.2 Rest of Middle East & Africa: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.4.6.4.3 Rest of Middle East & Africa: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.4.6.4.4 Rest of Middle East & Africa: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.5 South & Central America Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
10.5.1 Overview
10.5.2 South & Central America Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.5.3 South & Central America: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.5.3.1 South & Central America: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.5.3.2 South & Central America: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.5.4 South & Central America: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.5.5 South & Central America: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.5.6 South & Central America Breast Cancer Therapeutics Market, by Country
10.5.6.1 Brazil
10.5.6.1.1 Brazil Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.1.2 Brazil: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.5.6.1.2.1 Brazil: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.5.6.1.2.2 Brazil: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.5.6.1.3 Brazil: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.5.6.1.4 Brazil: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.5.6.2 Argentina
10.5.6.2.1 Argentina Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.2.2 Argentina: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.5.6.2.2.1 Argentina: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.5.6.2.2.2 Argentina: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.5.6.2.3 Argentina: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.5.6.2.4 Argentina: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
10.5.6.3 Rest of South & Central America
10.5.6.3.1 Rest of South & Central America Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.3.2 Rest of South & Central America: Breast Cancer Therapeutics Market, by Drug Therapy, 2020 2030 (US$ Million)
10.5.6.3.2.1 Rest of South & Central America: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.5.6.3.2.2 Rest of South & Central America: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020 2030 (US$ Million)
10.5.6.3.3 Rest of South & Central America: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020 2030 (US$ Million)
10.5.6.3.4 Rest of South & Central America: Breast Cancer Therapeutics Market, by Distribution Channel, 2020 2030 (US$ Million)
11. Breast Cancer Therapeutics Market Industry Landscape
11.1 Overview
11.2 Growth Strategies in Breast Cancer Therapeutics Market
11.3 Organic Growth Strategies
11.3.1 Overview
11.4 Inorganic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Eli Lilly and Co
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Eisai Co Ltd
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Novartis AG
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 AstraZeneca Plc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Pfizer Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Gilead Sciences Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Merck & Co Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Genentech Inc.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Teva Pharmaceutical Industries Ltd
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Amgen Inc
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms

ページTOPに戻る

Table of Contents

Summary

Breast Cancer Therapeutics Market Size and Forecast (2020–2030), Global and Regional Share, Trends, and Growth Opportunity Analysis

Coverage: Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

The breast cancer therapeutics market size is expected to grow from US$ 31,073.52 million in 2022 to US$ 63,967.05 million by 2030; it is estimated to record a CAGR of 9.4% during 2022 to 2030.

Breast cancer is when the breast's cells proliferate out of control. Breast cancer comes in several forms. Which breast cells develop into cancer determines the type of breast cancer. The ducts or lobules are where most breast cancers start. Blood and lymph vessels are two ways breast cancer can travel outside the breast. Its treatment depends on the stage of cancer. It may consist of chemotherapy, radiation, hormone therapy and surgery. The breast cancer therapeutics market growth is attributed to the growing burden of breast cancer and launch of several diagnostics and screening programs.

Personalized medicine involves tailoring treatment plans to individual patients on the basis of their genetic makeup, among other factors. This approach allows for highly targeted and effective treatments, as it considers the unique characteristics of each patient's cancer. Advancements in genomics and molecular diagnostics have made personalized medicine a viable option in breast cancer treatment. Healthcare providers can identify specific genetic mutations or biomarkers driving the cancer's growth by analyzing a patient's tumor at a molecular level. This information can then be used to select the most appropriate treatment options, such as targeted therapies or immunotherapies, that are likely to be the most effective for that particular patient. The use of personalized medicine in breast cancer therapeutics has the potential to significantly improve patient outcomes. For instance, in February 2022, NIH researchers developed a personalized breast cancer therapy approach, an experimental form of immunotherapy that uses a patient’s tumor-fighting immune cells to treat those with metastatic breast cancer, advancing personalized medicine.

By providing tailored treatments to individual patients, healthcare providers can increase the likelihood of successful outcomes and reduce the risk of unnecessary side effects. In addition to improving patient outcomes, personalized medicine also offers economic benefits. By selecting treatments that are more likely to be effective, healthcare providers can reduce healthcare costs associated with ineffective treatments and avoid unnecessary expenses. As advancements in genomics and molecular diagnostics progress, personalized medicine is likely to become increasingly accessible and integrated into standard treatment protocols in the coming years. Therefore, the increasing use of personalized medicine is anticipated to bring new growth trends in the breast cancer therapeutics market.

Distribution Channel -Based Insights

Based on distribution channel, the breast cancer therapeutics market is segmented into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market share in 2022. The hospital pharmacy plays a crucial role in the management of breast cancer therapeutics. They are responsible for compounding and dispensing, monitoring drug safety, medication management, educating patients, and other factors. Breast cancer is one of the most widespread cancers worldwide, and the demand for effective therapeutics is steadily increasing. Hospital pharmacies are responsible for procuring, storing, and dispensing chemotherapy medications and other treatments related to breast cancer to ensure that patients receive the right treatment in time. These pharmacies are also in authority to manage the inventory and storage of these drugs, ensuring that they are stored and handled in accordance with strict regulations. Their collaborative efforts with oncologists and healthcare teams ensure that breast cancer patients receive optimal, personalized therapeutics and comprehensive care throughout their treatment journey. Hospital pharmacies remain instrumental in delivering timely and effective breast cancer treatments, significantly impacting patients’ outcomes in battling the disease.

However, the online pharmacies segment is anticipated to register the highest CAGR during 2022–2030. Online pharmacies offer a wide array of breast cancer medications ranging from chemotherapy drugs to supportive therapies, often with home delivery services. Ensuring prescription verification and maintaining regulatory compliance, online pharmacies play a vital role in upholding the integrity of the healthcare system. They also provide convenience for patients who prefer discrete shopping or have limited mobility due to treatment. They also enable patients to compare prices and access a broader selection of breast cancer therapeutics. With services such as home delivery and patient support, online pharmacies continue to evolve, transforming the breast cancer treatment experience and breaking down geographical barriers for patients worldwide. In addition, an increasing number of patients have shifted to these pharmacies to acquire therapeutics due to their greater ease in terms of usage, which is fueling the growth of the segment.

Europe is the second leading region in the market. Breast cancer is a common type of cancer in the UK. As per the National Health Service (NHS), about one in seven women are diagnosed with breast cancer during their lifespan in Great Britain data. Each year, ~55,000 women are diagnosed with breast cancer.

Greater demand from the medical industry to treat breast cancer patients with novel therapeutics has led to greater investment in R&D, fueling the growth of the market. Companies invest in research and development to stay competitive and provide customers with cutting-edge and innovative products. In October 2021, Trodelvy, a new antibody treatment, was authorized to treat an aggressive form of cancer called ‘triple-negative breast cancer’ in the country. In November 2021, Sanofi invested US$ 180 million and entered into a new strategic collaboration with Owkin, a French-American AI start-up engaged in the discovery and development programs of four types of cancer, with a total payment of US$ 90 million. The collaboration supported Sanofi’s developing oncology portfolio in core areas such as breast cancer, lung cancer, and multiple myeloma to enhance clinical trial design and detect predictive biomarkers for diseases and treatment results.

The Italian government and national health institutes have launched several initiatives for the early detection and treatment of breast cancer. These programs include free mammograms for women aged 50–69 and a nationwide breast cancer screening program. In addition, as per the information provided by EURACTIV, the country has witnessed a strong rise in the number of specialized Breast Units, from 84 in 2012 to 173 in 2020. The country's growing number of breast units helps healthcare professionals offer treatment to patients with breast cancer. Thus, the abovementioned factors support the market growth in the region.

The American Cancer S0ociety, World Health Organization (WHO), National Institutes of Health, and US FDA are among the primary and secondary sources referred to while preparing the breast cancer therapeutics market report.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医薬）の最新刊レポート

The Insight Partners社の製薬分野での最新刊レポート

本レポートと同じKEY WORD（chemotherapy）の最新刊レポート

よくあるご質問

The Insight Partners社はどのような調査会社ですか?

The Insight Partnersはインドに本社を置く調査会社です。経験豊富な専門家チームを通じて、お客様に最適な調査と分析を提供することに専念しています。幅広い分野をカバーしていますがヘルスケ... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医薬）の最新刊レポート

The Insight Partners社の製薬分野での最新刊レポート

本レポートと同じKEY WORD（chemotherapy）の最新刊レポート

よくあるご質問

The Insight Partners社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?